Otenzepad

Research use only, not for human use.

Otenzepad is a selective antagonist of M2 mAChR with IC50s of 386 nM and 640 nM for rat heart and rabbit peripheral lung.

Otenzepad is a selective antagonist of M2 mAChR with IC50s of 386 nM and 640 nM for rat heart and rabbit peripheral lung.(In Vivo):In rats, Otenzepad (2 mg/kg; s.c.) significantly improved retention relative to vehicle controls. Otenzepad (0.5, 1 mg/kg; s.c.) significantly improved win-stay acquisition. In mice, Otenzepad (0.3, 1.0, or 3.0 mg/kg, i.p.) reverses the effects of insulin on memory and potentiates the effects of glucose.

——

Otenzepad (0.5, 1 mg/kg, s.c., in rats) significantly improved win-stay acquisition relative to vehicle-injected controls.Otenzepad (2 mg/kg, s.c., in rats) significantly improved retention relative to vehicle controls.Otenzepad (0.3, 1.0, or 3.0 mg/kg, ip, in mice) potentiates the effects of glucose and reverses the effects of insulin on memory. Animal Model:Forty-eight male Long-Evans rats (325-350 g).Dosage:0.25, 0.5, 1.0 and 2.0 mg/kg.Administration:S.C. on the dorsum of the neck once.Result:Doses of 0.5 and 1.0 mg/kg significantly improved acquisition relative to vehicle controls, while doses of 0.25 and 2.0 mg/kg had no effect.Animal Model:Adult male Swiss mice (age 60–70 days; weight 25-30 g).Dosage:0.3, 1.0, or 3.0 mg/kg.Administration:IP once.Result:Enhanced retention in an inverted-U dose–response manner, with significant enhancement seen at 1.0 mg/kg (U15,15 = 49, p < 0.02, compared with saline-saline-injected control group).

AF-DX 116

Cell Cycle/DNA Damage

AChR

CYP1A1| CYP1A2| CYP2B1

——

——

102394-31-0

421.545

C24H31N5O2

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (59.31 mM)

CCN(CC)CC1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12

——

(-20℃)

With Ice Pack

≥ 2 years